Repligen Stock Price, News & Analysis

Repligen Corporation (NASDAQ: RGEN) successfully closed its underwritten public offering of 1.725 million shares at $181 each, generating gross proceeds of approximately $312.2 million. After deducting fees, the net proceeds are expected to be about $298 million, intended for working capital and general corporate purposes, including potential investments in complementary businesses. The offering included full exercise of the underwriters’ option for an additional 225,000 shares. The company has no current agreements for acquisitions.

EC Mergers & Acquisitions has announced the successful sale of ARTeSYN BioSolutions to Repligen Corporation for a total transaction value of $200M. This includes $130M in cash and $70M in Repligen common stock. ARTeSYN specializes in single-use solutions for bioprocessing, anticipating $30M in pro forma revenue for 2020. The acquisition is expected to generate approximately $33M-$36M in revenue for Repligen in 2021, enhancing its portfolio in bioprocessing technologies.

Repligen Corporation (NASDAQ: RGEN) has priced a public offering of 1.5 million shares at $181 each, aiming to raise approximately $271.5 million before expenses. The underwriters hold a 30-day option for an additional 225,000 shares. Proceeds will be used for working capital and general corporate purposes, including potential acquisitions and investments. The offering is scheduled to close around December 10, 2020, pending customary conditions. J.P. Morgan and Stifel are the lead managers of the offering.

Repligen Corporation (NASDAQ: RGEN) has commenced a public offering of 1.5 million shares of its common stock, with a potential additional 225,000 shares available for underwriters. Proceeds will be used for working capital and to explore acquisitions, though no current agreements exist. The offering is subject to market conditions, and completion timing is uncertain. J.P. Morgan and Stifel are managing the offering, which will follow a previously filed shelf registration statement with the SEC.

Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $94.1 million, marking a 35% year-over-year growth with 31% organic growth. The company raised its full-year revenue guidance to $348-$352 million, implying a 29%-30% total revenue growth. COVID-related revenues contributed approximately 14% to quarterly revenue and 55% to growth. Repligen also completed the acquisition of Non-Metallic Solutions and plans to acquire ARTeSYN Biosolutions, enhancing its systems strategy.

Repligen Corporation (NASDAQ:RGEN) announced a definitive agreement to acquire ARTeSYN Biosolutions for approximately $200 million, enhancing its portfolio of single-use downstream bioprocessing systems. The acquisition is expected to generate around $30 million in pro forma revenue for ARTeSYN in 2020 and contribute $33 to $36 million in 2021, with breakeven adjusted earnings per share in the same year and accretive results anticipated in 2022. This move complements previous acquisitions of Engineered Molding Technologies and Non-Metallic Solutions, positioning Repligen as a leading player in the bioprocessing market.

Repligen Corporation (NASDAQ:RGEN) will announce its third quarter 2020 financial results on November 5, 2020, before the market opens. A conference call will take place at 8:30 a.m. EST to discuss the results and business updates. Investors can access the call by phone or via a webcast on the company’s Investor Relations page. Repligen is a global life sciences company focused on developing bioprocessing technologies that enhance the manufacturing of biological drugs.

Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $87.5 million, a year-over-year increase of 24% with 19% organic growth. The company raised its fiscal year revenue guidance to $332-$340 million, reflecting anticipated margins expansion and continued demand amid COVID-19 vaccine programs. Gross margin improved to 57.9%, with EPS rising to $0.30 from $0.17 a year ago. The acquisition of Engineered Molding Technology supports RGEN's strategic focus on expanding its single-use portfolio.

On June 15, 2020, Repligen Corporation (NASDAQ:RGEN) announced the appointment of Carrie Eglinton Manner to its Board of Directors. With over 23 years in the healthcare sector, she brings extensive leadership experience, notably as Senior VP at Quest Diagnostics and former President & CEO at GE Healthcare. Her expertise in business growth and profitability is expected to support Repligen's innovation-based strategy. The Board expressed confidence in her ability to enhance company operations and expand its market presence in bioprocessing technologies.